Trudel, Suzanne
Lendvai, Nikoletta
Popat, Rakesh
Voorhees, Peter M.
Reeves, Brandi
Libby, Edward N.
Richardson, Paul G.
Hoos, Axel
Gupta, Ira
Bragulat, Veronique
He, Zangdong
Opalinska, Joanna B.
Cohen, Adam D.
Funding for this research was provided by:
GlaxoSmithKline
Article History
Received: 31 December 2018
Revised: 15 February 2019
Accepted: 25 February 2019
First Online: 20 March 2019
Competing interest
: A.D.C. is a consultant for and a member of an advisory board for GlaxoSmithKline and Celgene, is a member of an advisory board for Janssen, Takeda, Oncopeptides, Kite Pharma, Seattle Genetics and Bristol-Myers Squibb, and has received research funding from Bristol-Myers Squibb and Novartis. N.L. has received research funding from GlaxoSmithKline, Takeda, Karyopharm, Sanofi and Amgen and served as consultant for Karyopharm and Amgen. R.P. has received honoraria from Janssen, Takeda, Celgene and Amgen, and travel support to attend meetings from Janssen, Takeda and Celgene. P.G.R. has received research funding from Celgene, Takeda, Oncopeptides and BMS, and is a member of advisory committees for Celgene, Oncopeptides, Janssen and Takeda. S.T. is a consultant for and has received honoraria from Amgen and Celgene, has received honoraria from Takeda and AbbVie, is a consultant for Novartis, and has received research support from Janssen. P.M.V. is a consultant for Amgen, Celgene, Janssen, Bristol-Myers Squibb, Novartis, Takeda, Oncopeptides and Teneo-Bio, and has participated in speakers’ bureaux for Amgen, Celgene and Janssen. I.G., A.H., V.B., J.B.O. and Z.H. are employees of and hold stocks/shares in GlaxoSmithKline. B.R. and E.N.L. declare no competing interests.